The Department of Veterans Affairs (VA) is preparing to issue Request for Proposal (RFP) #36E79725R0043 to procure the Respiratory Syncytial Virus Vaccine (RSV Vaccine) for VA, Department of Defense (DoD), Bureau of Prisons (BOP), Indian Health Service (IHS), and Federal Health Care Centers (FHCC). This procurement is unrestricted and aims to secure a reliable supply source for one year, with options for four additional yearly periods. The expected annual requirement is approximately 248,803 vials of the RSV Vaccine, which will be distributed through the VA’s and DoD’s Pharmaceutical Prime Vendor Programs. The RFP is set to be issued on or around June 2, 2025, with a response deadline of June 16, 2025. Offerors are required to provide detailed information on the vaccine products, including package sizes and unique NDC numbers. The awarded vaccine will serve as a mandatory source unless deemed clinically inappropriate for certain patient demographics. Interested parties should regularly check SAM.gov for updates, and any inquiries should be directed to the designated contracting officers via email.
The document outlines a federal solicitation by the Department of Veterans Affairs (VA) for the procurement of Respiratory Syncytial Virus (RSV) vaccines through its Pharmaceutical Prime Vendor (PPV) program. The solicitation mandates that bidders provide prices for the base year and four additional option years, aiming for consistency in availability and volume-based pricing. The contract will be awarded to the entity that offers the most competitive pricing for specified quantities of vaccines. Offerors must comply with several stipulations, including maintaining unique National Drug Codes (NDCs) and adhering to FDA guidelines.
The contract will establish a mandatory supply source unless specific clinical exceptions arise. It incorporates various federal acquisition clauses and emphasizes compliance with Drug Supply Chain Security Act (DSCSA) regulations regarding drug tracking. Offerors must submit comprehensive proposals, acknowledging all contract terms, and demonstrate manufacturing capability consistent with FDA standards. Regular reporting and fee payment obligations are also mandated.
This document illustrates the VA's structured procurement process that aligns with federal regulations and emphasizes the importance of compliance and quality assurance in pharmaceutical supplies, reflecting the government's commitment to efficient health care delivery.
The document outlines an amendment to a solicitation related to a national contract for the respiratory syncytial virus (RSV) vaccine, managed by the Department of Veterans Affairs (VA). This amendment clarifies that the awarded RSV vaccine will be a mandatory supply for adults, with exceptions for clinical inappropriateness, such as patients falling outside the specified age range. The document emphasizes that all other terms and conditions of the original solicitation remain unchanged. The amendment is formally acknowledged by the contracting officer, Nicholas I. McGregor, highlighting adherence to established procurement procedures. This communication is essential to ensure that all participating offerors are informed of the changes to the contract, maintaining compliance and clarity in the government contracting process.